Pliant Therapeutics

Forecast & Rating5 analysts currently cover Pliant Therapeutics, with about 0.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $2.50, about 135.8% upside from the current price of $1.06. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 3.5% of past price targets were eventually met, which adds credibility. For you, this means most institutions are cautious on Pliant Therapeutics's outlook. Data as of Jun 30, 2026; for reference only and not investment advice.